Last Published:  07/31/19 10:05:33 AM (Central)
Short Title: 2022 CVD/Late CNS biomarker & CM ID
Responsible HRP Element: Space Radiation
Collaborating Org(s):
Funding Status: Planned-Funded - Task expected to be within budget
Procurement Mechanism(s):
  • Aim 1 (CVD): Validate surrogate endpoint biomarkers, including standard of care clinical markers, for monitoring space radiation-induced late cardiovascular diseases for use in risk assessment model development and evaluation of protective countermeasures.

  • Aim 2 (Late CNS): Define adverse outcome pathways and potential biomarkers associated with CNS functional changes and late neurodegenerative diseases

  • Aim 3 (CVD): Evaluate standard of care clinical protective measures, such as exercise, dyslipidemia drugs, anti-inflammatory drugs, diet, as mitigation strategy for late cardiovascular diseases.

  • Aim 4 (late CNS): Determine whether CVD countermeasures are effective in mitigating adverse CNS effects.

Resources (None Listed)
RiskRisk of Acute (In-flight) and Late Central Nervous System Effects from Radiation Exposure
You are here!Task2022 NSCOR: CVD/Late CNS clinical MCM Assessment

RiskRisk of Adverse Cognitive or Behavioral Conditions and Psychiatric Disorders
You are here!Task2022 NSCOR: CVD/Late CNS clinical MCM Assessment

RiskRisk of Cardiovascular Disease and Other Degenerative Tissue Effects From Radiation Exposure and Secondary Spaceflight Stressors
GapDegen - 2: What are the adverse outcome pathways associated with degenerative tissues changes in the cardiovascular, cerebrovascular, lens, immune, digestive, endocrine, and other tissue systems? What are the key events or hallmarks, their time sequence, and their associated biomarkers?
GapDegen - 3: What are the progression rates and latency periods for radiation-induced degenerative diseases, and how do progression rates depend on age, sex, radiation type, or other physiological or environmental factors?
GapDegen - 5: What quantitative procedures or theoretical models are needed to extrapolate molecular, cellular, animal results, or clinical human data to predict degenerative tissue risks in astronauts? How can human epidemiology data best support these procedures or models?
GapDegen - 6: What are the most effective medical or dietary countermeasures to mitigate degenerative tissue risks? Are there common pathways that will benefit multiple tissues?
You are here!Task2022 NSCOR: CVD/Late CNS clinical MCM Assessment